Research

Hormonal

Tirzepatide treatment produces significant body weight, waist circumference, and waist-to-height ratio reductions in women across all reproductive stages (premenopausal, perimenopausal, and postmenopausal), demonstrating efficacy irrespective of menopausal status.

If you are a woman with overweight or obesity, whether you are premenopausal, perimenopausal, or postmenopausal, tirzepatide (15mg weekly) is highly effective for significant weight loss. Do not assume your reproductive stage limits your ability to lose weight with this treatment; the data shows robust results across all stages.

GoodSupportsHIGH confidence
In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.
Beverly G. Tchang et al. · Obesity · 2025

Why this rating

Post hoc analysis of phase 3 randomized controlled trials (SURMOUNT-1, -3, -4) with large sample sizes (n=2542 women), though retrospective categorization of reproductive stage is a limitation.

Source

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the <scp>SURMOUNT</scp> program

Beverly G. Tchang et al. · Obesity · 2025

DOI 10.1002/oby.24254

rct · n=2542Cited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →